Company news

Vir Biotechnology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 11, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 6, 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

April 29, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

April 23, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

March 20, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 12, 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

February 18, 2025

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

February 11, 2025

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

January 7, 2025

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

December 11, 2024

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

November 25, 2024

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 24, 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

November 17, 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

November 17, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

November 14, 2024

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

October 30, 2024

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

October 16, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024

October 14, 2024

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

October 2, 2024

Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer

September 9, 2024

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

September 8, 2024

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 21, 2024

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

July 31, 2024

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

July 31, 2024

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

July 17, 2024

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

June 25, 2024

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

June 4, 2024

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

May 28, 2024

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

May 22, 2024

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

May 21, 2024

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

May 20, 2024

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

May 12, 2024

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024

Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024

April 29, 2024

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

April 17, 2024

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

April 10, 2024

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

March 4, 2024

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

February 22, 2024

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024

Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer

February 19, 2024

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

January 31, 2024

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

December 12, 2023

Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference

December 5, 2023

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

November 12, 2023

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

November 9, 2023

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

November 7, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 30 decks. Every deck is listed under its year.